Core Insights - Xeltis has secured nearly €50 million in new financing, including up to €37.5 million from the European Investment Bank (EIB) and €10 million from existing investors, to advance the commercialization of its product aXess [1][5] - The financing follows positive clinical data from Xeltis' EU pivotal trial for aXess, which demonstrated significant improvements in patency rates and reduced infection rates compared to standard care [2][5] - The investment positions Xeltis to confidently move towards commercialization and expand its production capabilities [3][4] Financing Details - The financing consists of €37.5 million from the EIB, with €10 million upfront and an option for an additional €27.5 million, alongside €10 million from existing investors including EQT and Invest-NL [1][5] - The funds will be used for scaling production, hiring staff, and further developing Xeltis' broader pipeline of transformative implants [1][4] Clinical Trial Results - The EU pivotal trial for aXess met its primary endpoints, showing standout sustained patency rates and significant improvements in key measures such as infection rates and intervention frequency [2][5] - A US pivotal trial for aXess is also in progress, with interim data expected in 2026 [2] Product Development - Xeltis' proprietary Endogenous Tissue Restoration (ETR) platform technology is utilized in developing aXess, which aims to regenerate the patient's own tissue [6] - The company is also advancing its second product, Xabg, a coronary artery bypass conduit, which has shown exceptionally positive 24-month follow-up results [4][6] Company Background - Xeltis is a medtech company focused on developing implants that create living and long-lasting vessels, addressing the needs of patients requiring hemodialysis access and cardiovascular replacements [5][6] - The company is based in the Netherlands and the USA, with a diverse investor base including DaVita Venture Group and the European Innovation Council [6]